The U.S. Department of Justice told industry audiences it is expanding enforcement under the False Claims Act, with drug pricing, cybersecurity, and fraud detection now central priorities. In a keynote delivered at the Pharmaceutical Compliance Congress, Brenna Jenny, deputy assistant attorney general in the Commercial Litigation Branch, described a “war on fraud” posture and pointed to record settlement levels. Jenny said DOJ reached fiscal-year 2025 settlements and judgments exceeding $6.8 billion, with prescription drugs driving enforcement volume. She also flagged cases involving reported Average Wholesale Price practices and the use of data analytics to identify potential FCA targets. The message is a concrete signal to pharma compliance teams that enforcement scrutiny will remain broad, data-driven, and tightly linked to pricing and reporting practices.